ImmunoGen reports Phase I data for IMGN779 in AML

ImmunoGen Inc. (NASDAQ:IMGN) reported data from the dose-escalation portion of an open-label, U.S. Phase I trial in patients with relapsed or

Read the full 210 word article

User Sign In